Condition

Pheochromocytoma clinical trials and research

• 22Clinical trials
• 2NIH research projects
• 12Countries

Newest Pheochromocytoma clinical trials

All recruiting trials (22)

• Belzutifan and catecholamine metabolism in pheochromocytoma/paraganglioma

  This study tests whether Belzutifan can change how catecholamines are produced and broken down in adults with pheochromocytoma or paraganglioma.

  Recruiting Phase 2 Cambridge University Hospitals NHS Foundation Trust · Cambridge, Cambridgeshire · NCT07680205

• Cardiovascular Outcomes After Adrenalectomy for Pheochromocytoma and Non-secreting Tumors

  This study tests how often and what kinds of cardiovascular problems occur after adrenalectomy for pheochromocytoma or non-secreting tumors.

  Recruiting Central Hospital, Nancy, France · Vandœuvre-lès-Nancy, Lorraine · NCT07200245

• NET- and somatostatin-targeted PET/SPECT imaging to find and stage neuroblastoma and pheochromocytoma/paraganglioma

  This study will try different PET and SPECT tracers to see if they can accurately find and stage tumors in children and adults with neuroblastoma or pheochromocytoma/paraganglioma.

  Recruiting Nanjing First Hospital, Nanjing Medical University · Nanjing, Jiangsu · NCT07195500

• Evaluating 18F-MFBG PET Imaging for Pheochromocytoma

  This study is testing a new imaging method called 18F-MFBG PET to see if it can help people with pheochromocytoma get better and faster pictures of their tumors compared to traditional methods.

  Recruiting at 2 sites First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang and 1 other locations · NCT06813742

• Combining Lutathera® and Olaparib for treating recurrent solid tumors in children and adolescents

  This study is testing if combining Lutathera® with olaparib can help children and teenagers with hard-to-treat solid tumors that have certain receptors.

  Recruiting Phase 1/2 Fundación de investigación HM · Boadilla del Monte, Madrid · NCT06607692

• Registry for Rare Diseases

  This study is creating a detailed registry to collect information on rare diseases like amyloidosis and sarcoidosis to help improve how they are diagnosed and treated.

  Recruiting Hospital Italiano de Buenos Aires · Buenos Aires, Buenos Aires · NCT06573723

• Understanding genetic causes of neuroendocrine tumors in Mexican patients

  This study is trying to find out the genetic changes that cause neuroendocrine tumors in Mexican patients to help develop better treatments.

  Recruiting at 3 sites Universidad Nacional Autonoma de Mexico · Mexico City, Mexico City and 2 other locations · NCT06523582

• Examining the immune system in hereditary pheochromocytoma and paraganglioma

  This study is testing how the immune system works in people with pheochromocytoma and paraganglioma, especially those with a family history of these tumors, to see if it can help us find better treatments.

  Recruiting Radboud University Medical Center · Nijmegen, Gelderland · NCT06444607

• Targeted treatment for advanced gastrointestinal neuroendocrine tumors and pheochromocytoma

  This study is testing a new drug to see if it can help people with advanced gastrointestinal neuroendocrine tumors and pheochromocytoma who have already tried other treatments.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06427798

• Advancing genomic medicine using electronic health records

  This study is trying to see if using electronic health records and helpful reminders can get more patients tested for genetic conditions in a way that doctors can easily use.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT06377033

• Treatment for neuroendocrine tumors using 177Lu-DOTATOC

  This study is testing a new treatment called 177Lu-DOTATOC to see if it can help patients with certain types of neuroendocrine tumors when other treatments aren't working.

  Recruiting Phase 2 Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Cesena, Forlì-Cesena and 1 other locations · NCT06045260

• Omitting preoperative alpha-blockade for normotensive pheochromocytoma

  This study is testing whether skipping a common medication before surgery can help patients with certain tumors avoid low blood pressure during and after their operation without putting them at risk.

  Recruiting Phase 4 Seoul National University Hospital · Seoul · NCT05702944

• Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

  This study is testing a new type of treatment using targeted alpha-particle therapy to see if it can help people with advanced neuroendocrine tumors that have a specific protein called SSTR2.

  Recruiting at 20 sites Phase 1/2 Perspective Therapeutics · Jacksonville, Florida and 19 other locations · NCT05636618

• Evaluating PARP-1 Expression in Pheochromocytoma and Paraganglioma Using PET/CT Imaging

  This study is testing a new imaging method to see how a specific protein is expressed in tumors of patients with pheochromocytoma or paraganglioma before they receive treatment.

  Recruiting Early Phase 1 Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT05636540

• Using 18F-MFBG PET/CT to evaluate neural crest tumors

  This study is testing a new imaging method using 18F-MFBG to see if it can help diagnose and better understand tumors like pheochromocytoma, paraganglioma, and neuroblastoma in patients.

  Recruiting Early Phase 1 Peking Union Medical College Hospital · Beijing, Dongcheng · NCT05069220

• Gene modified immune cells for treating advanced melanoma and metastatic solid tumors

  This study is testing if modified immune cells can safely target and attack advanced melanoma and other solid tumors in patients after they receive chemotherapy.

  Recruiting at 3 sites Phase 1 Stanford University · Duarte, California and 2 other locations · NCT04119024

• Evaluation of follow-up care for patients with pheochromocytoma and paraganglioma

  This study is testing if a special follow-up care approach can help people with pheochromocytomas and paragangliomas live healthier and longer lives compared to standard care.

  Recruiting Ludwig-Maximilians - University of Munich · Zurich · NCT03344016

• Treatment for inoperable pheochromocytoma and paraganglioma using Lu-177-DOTATATE

  This study is testing if a new treatment called Lu-177-DOTATATE can help people with inoperable pheochromocytoma and paraganglioma by delaying the return of their tumors.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT03206060

• Genetic analysis of tumors related to pheochromocytoma and paraganglioma

  This study is trying to find genetic changes in people with pheochromocytomas and paragangliomas to help improve diagnosis and treatment options for them and their families.

  Recruiting The University of Texas Health Science Center at San Antonio · San Antonio, Texas · NCT03160274

• Investigating adrenal tumors and their treatments

  This study looks at adrenal tumors and their treatments to see how they develop and what therapies might help patients feel better.

  Recruiting University of Wuerzburg · Würzburg · NCT00669266

• Using Iodine I 131 Metaiodobenzylguanidine to treat advanced neuroblastoma and pheochromocytoma

  This study is testing if a special treatment called Iodine I 131 Metaiodobenzylguanidine can help people with hard-to-treat neuroblastoma and pheochromocytoma feel better when other treatments haven’t worked.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT00107289

• Improving diagnosis and treatment of pheochromocytoma

  This study is testing new ways to find and treat pheochromocytomas, which are tumors from the adrenal glands, to help improve care for people with this condition.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT00004847

NIH-funded research (2)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Understanding how genetic background affects rare tumors and their treatment responses

  This study is looking at how your genetic background might affect the way rare tumors called pheochromocytomas and paragangliomas behave and respond to treatment, especially for patients from underrepresented racial and ethnic groups, to help find better ways to detect and treat these tumors.

  NIH research University of Texas Hlth Science Center · San Antonio, United States · NIH-10922102

• Understanding genetic factors in hereditary paraganglioma and pheochromocytoma syndrome

  This study is looking at how certain genes might affect the chances of developing adrenal tumors called paragangliomas and pheochromocytomas, so if you or someone you know is at risk, this research could help improve testing and treatment options for you.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-10834053

Related topics

Quick answers

How many Pheochromocytoma clinical trials are recruiting right now?

22, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 12 countries. The most sites are in United States (9 trials), China (3 trials), Argentina (1 trial), South Korea (1 trial), Germany (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 1/2: 3, Early Phase 1: 2, Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →